Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
meningococcal B rLP2086 vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | dose level 1 rLP2086 vaccine |
| 2 | EXPERIMENTAL | dose level 2 rLP2086 vaccine |
| 3 | EXPERIMENTAL | dose level 3 rLP2086 vaccine |
| 4 | PLACEBO_COMPARATOR | normal saline (placebo) |
| Name | Type | Description |
|---|---|---|
| meningococcal B rLP2086 vaccine. | BIOLOGICAL | vaccine, 0.5 mL, 0 - 2 - 6 to 9 months |
| normal saline (placebo) | OTHER | vaccine, 0.5 mL, 0 - 2 - 6 to 9 months |
Inclusion Criteria: * Healthy male or female subjects between the ages of \>=11 and \<=18 years at the time of enrollment. * Negative urine pregnancy test for all female subjects. * Parent/legal guardian or subject under supervision of the parent/legal guardian must be able to complete all relevant...
Meningococcal B rLP2086 vaccine is an investigational vaccine being studied for the prevention of meningitis and meningococcal disease. It is designed to protect against infections caused by Neisseria meningitidis serogroup B. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
Meningococcal B rLP2086 vaccine is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The vaccine is currently in Phase 2 clinical development for the prevention of meningococcal disease.
Meningococcal B rLP2086 vaccine is in Phase 2 clinical development. It is an investigational vaccine and has not yet received regulatory approval. The vaccine is being studied for its safety and immunogenicity in adolescents, with one completed Phase 2 trial.
Meningococcal B rLP2086 vaccine has been evaluated in one completed Phase 2 clinical trial, identified as NCT00808028. This study assessed the safety and immunogenicity of the vaccine in adolescents aged 11 years and older, enrolling 538 participants across Australia, Poland, and Spain.
Meningococcal B rLP2086 vaccine is the investigational name for the vaccine that was later marketed as Trumenba. The clinical trial data provided refers to the vaccine under its developmental name, rLP2086, which is the same product that received approval for meningococcal serogroup B prevention.